Results 31 to 40 of about 2,794,922 (242)

A DR4, DR5 Targeting Conjugated TRAIL Treatment for Colorectal Carcinogenesis: A Way to Future? [PDF]

Pharmaceutical Sciences
TRAIL or tumor necrosis factor-related apoptosis-inducing ligand has been one of the major frontiers for the chemotherapeutic approach to treating carcinogenesis.
Parikshit Roychowdhury, Indhumathi Thirugnanasambandham, Anindita De, Mirunalini Gobinath, Samanwita Khanra, Veera Venkata Satyanarayana Reddy Karri, Nihar Ranjan Bhuyan, Gowthamrajan Kuppusamy   +7 more
doaj   +1 more source

Tristetraprolin Posttranscriptionally Downregulates TRAIL Death Receptors

Cells, 2020
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has attracted attention as a potential candidate for cancer therapy. However, many primary cancers are resistant to TRAIL, even when combined with standard chemotherapy.
Won Hyeok Lee, Myung Woul Han, Song Hee Kim, Daseul Seong, Jae Hee An, Hyo Won Chang, Sang Yoon Kim, Seong Who Kim, Jong Cheol Lee   +8 more
doaj   +1 more source

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. [PDF]

, 2012
Thus, we evaluated the immunofluorescence pattern of TRAIL-receptors and E-cadherin to assess the fraction of membrane-bound TRAIL-receptors in 231 selected patients with early-stage CRC undergoing surgical treatment only.
Göke, Burkhard, Thomas Kirchner (109827), Rene Jackstadt, Gallmeier, Eike, Thomas Kirchner, Gerbes, Alexander L., Kriegl, Lydia, Eike Gallmeier, Jackstadt, Rene, Alexander L Gerbes, Burkhard Göke (109829), De Toni, Enrico N., Eike Gallmeier (109823), Enrico N De Toni, Burkhard Göke, Horst, David, Andreas Jung, Rene Jackstadt (109815), David Horst, Jung, Andreas, Antonia Rizzani (109811), Heiko Hermeking (109819), Alexander L. Gerbes (109825), Kirchner, Thomas, Andreas Jung (109804), David Horst (109808), Enrico N. De Toni (109830), Lydia Kriegl, Rizzani, Antonia, Hermeking, Heiko, Heiko Hermeking, Lydia Kriegl (109801), Antonia Rizzani, Hermeking Heiko, Rizzani Antonia, Gallmeier Eike, Jackstadt Rene, Jung Andreas, De Toni Enrico N., Göke Burkhard, Horst David, Kriegl Lydia, Gerbes Alexander L., Kirchner Thomas   +43 more
core   +2 more sources

Death Receptors and Their Ligands in Atherosclerosis [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
Atherosclerosis is characterized by the accumulation of a fibro-fatty plaque consisting of immune cells, vascular smooth muscle cells (VSMCs), vascular endothelial cells (ECs), and extracellular matrix, surrounding a lipid-rich core. The complexity of atherosclerosis is highlighted by the multifaceted effects that apoptosis and proliferation of ...
Mary M, Kavurma, Nicole Y, Tan, Martin R, Bennett   +2 more
openaire   +2 more sources

Theaflavin-3,3′-Digallate Suppresses Human Ovarian Carcinoma OVCAR-3 Cells by Regulating the Checkpoint Kinase 2 and p27 kip1 Pathways

Molecules, 2019
Theaflavin-3,3′-digallate (TF3) is a unique polyphenol in black tea. Epidemiological studies have proved that black tea consumption decreases the incidence rate of ovarian cancer.
Ying Gao, Junfeng Yin, Youying Tu, Yi Charlie Chen   +3 more
doaj   +1 more source

Death receptors in chemotherapy and cancer [PDF]

Oncogene, 2004
Apoptosis, the cell's intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies such as chemotherapy, gamma-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target ...
Klaus-Michael, Debatin, Peter H, Krammer
openaire   +2 more sources

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking

Stress Biology, 2023
BRI1-ASSOCIATED KINASE 1 (BAK1/SERK3) and its closest homolog BAK1-LIKE 1 (BKK1/SERK4) are leucine-rich repeat receptor kinases (LRR-RKs) belonging to the SOMATIC EMBRYOGENESIS RECEPTOR KINASE (SERK) family.
Vahid Fallahzadeh-Mamaghami, Hannah Weber, Birgit Kemmerling   +2 more
doaj   +1 more source

Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. [PDF]

PLoS ONE, 2014
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) mediates apoptosis in cancer cells through death receptors DR4 and DR5 preferring often one receptor over another in the cells expressing both receptors.
Maxim L Bychkov, Marine E Gasparian, Dmitry A Dolgikh, Mikhail P Kirpichnikov   +3 more
doaj   +1 more source

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL

Frontiers in Cell and Developmental Biology, 2021
Tumor necrosis factor-associated ligand inducing apoptosis (TRAIL) induces apoptosis through the death receptors (DRs) 4 and 5 expressed on the cell surface. Upon ligand stimulation, death receptors are rapidly internalized through clathrin-dependent and
Artem A. Artykov, Anne V. Yagolovich, Anne V. Yagolovich, Dmitry A. Dolgikh, Dmitry A. Dolgikh, Mikhail P. Kirpichnikov, Mikhail P. Kirpichnikov, Daria B. Trushina, Marine E. Gasparian   +8 more
doaj   +1 more source

Cancer Cell Growth Inhibitory Effect of Bee Venom via Increase of Death Receptor 3 Expression and Inactivation of NF-kappa B in NSCLC Cells

Toxins, 2014
Our previous findings have demonstrated that bee venom (BV) has anti-cancer activity in several cancer cells. However, the effects of BV on lung cancer cell growth have not been reported.
Kyung Eun Choi, Chul Ju Hwang, Sun Mi Gu, Mi Hee Park, Joo Hwan Kim, Joo Ho Park, Young Jin Ahn, Ji Young Kim, Min Jong Song, Ho Sueb Song, Sang-Bae Han, Jin Tae Hong   +11 more
doaj   +1 more source